<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35523582</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2373-2822</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>eNeuro</Title><ISOAbbreviation>eNeuro</ISOAbbreviation></Journal><ArticleTitle>Inhibition of Crmp1 Phosphorylation at Ser522 Ameliorates Motor Function and Neuronal Pathology in Amyotrophic Lateral Sclerosis Model Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ENEURO.0133-22.2022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1523/ENEURO.0133-22.2022</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder that affects upper and lower motor neurons; however, its pathomechanism has not been fully elucidated. Using a comprehensive phosphoproteomic approach, we have identified elevated phosphorylation of Collapsin response mediator protein 1 (Crmp1) at serine 522 in the lumbar spinal cord of ALS model mice overexpressing a human superoxide dismutase mutant (SOD1<sup>G93A</sup>). We investigated the effects of Crmp1 phosphorylation and depletion in <i>SOD1<sup>G93A</sup></i> mice using Crmp1<sup>S522A</sup> (Ser522&#x2192;Ala) knock-in (<i>Crmp1<sup>k</sup></i><sup>i</sup><i><sup>/ki</sup></i> ) mice in which the S522 phosphorylation site was abolished and <i>Crmp1</i> knock-out (<i>Crmp1</i><sup>-/-</sup>) mice, respectively. <i>Crmp1<sup>ki</sup></i><sup>/</sup><i><sup>ki</sup></i> /<i>SOD1<sup>G93A</sup></i> mice showed longer latency to fall in a rotarod test while <i>Crmp1</i><sup>-/-</sup>/<i>SOD1<sup>G93A</sup></i> mice showed shorter latency compared with <i>SOD1<sup>G93A</sup></i> mice. Survival was prolonged in <i>Crmp1<sup>ki</sup></i><sup>/</sup><i><sup>ki</sup></i> /<i>SOD1<sup>G93A</sup></i> mice but not in <i>Crmp1</i><sup>-/-</sup>/<i>SOD1<sup>G93A</sup></i> mice. In agreement with these phenotypic findings, residual motor neurons and innervated neuromuscular junctions (NMJs) were comparatively well-preserved in <i>Crmp1<sup>ki</sup></i><sup>/</sup><i><sup>ki</sup></i> /<i>SOD1<sup>G93A</sup></i> mice without affecting microglial and astroglial pathology. Pathway analysis of proteome alterations showed that the sirtuin signaling pathway had opposite effects in <i>Crmp1<sup>ki</sup></i><sup>/</sup><i><sup>ki</sup></i> /<i>SOD1<sup>G93A</sup></i> and <i>Crmp1</i><sup>-/-</sup>/<i>SOD1<sup>G93A</sup></i> mice. Our study indicates that modifying CRMP1 phosphorylation is a potential therapeutic strategy for ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Asano et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asano</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Haruko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan haruko0224@gmail.com ftanaka@yokohama-cu.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamoto</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tada</LastName><ForeName>Mikiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Yayoi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Advanced Medical Research Center, Yokohama City University, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ryoji</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Hiroya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komiya</LastName><ForeName>Hiroyasu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubota</LastName><ForeName>Shun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashiguchi</LastName><ForeName>Shunta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunii</LastName><ForeName>Misako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goshima</LastName><ForeName>Yoshio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, School of Medicine, Tokyo Women's Medical University, Tokyo 162-8666, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Fumiaki</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9961-2693</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan haruko0224@gmail.com ftanaka@yokohama-cu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>eNeuro</MedlineTA><NlmUniqueID>101647362</NlmUniqueID><ISSNLinking>2373-2822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">CRMP1</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>6</Day><Hour>21</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35523582</ArticleId><ArticleId IdType="pmc">PMC9131721</ArticleId><ArticleId IdType="doi">10.1523/ENEURO.0133-22.2022</ArticleId><ArticleId IdType="pii">ENEURO.0133-22.2022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arbez N, Ratovitski T, Roby E, Chighladze E, Stewart JC, Ren M, Wang X, Lavery DJ, Ross CA (2017) Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity. J Biol Chem 292:19238&#x2013;19249. 10.1074/jbc.M117.782300</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.782300</ArticleId><ArticleId IdType="pmc">PMC5702665</ArticleId><ArticleId IdType="pubmed">28972180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bk B, Skuntz S, Prochazkova M, Kesavapany S, Amin ND, Shukla V, Grant P, Kulkarni AB, Pant HC (2019) Overexpression of the Cdk5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model. Hum Mol Genet 28:3175&#x2013;3187. 10.1093/hmg/ddz118</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz118</ArticleId><ArticleId IdType="pmc">PMC6859439</ArticleId><ArticleId IdType="pubmed">31189016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bretin S, Reibel S, Charrier E, Maus-Moatti M, Auvergnon N, Thevenoux A, Glowinski J, Rogemond V, Pr&#xe9;mont J, Honnorat J, Gauchy C (2005) Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol 486:1&#x2013;17. 10.1002/cne.20465</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.20465</ArticleId><ArticleId IdType="pubmed">15834957</ArticleId></ArticleIdList></Reference><Reference><Citation>Charrier E, Mosinger B, Meissirel C, Aguera M, Rogemond V, Reibel S, Salin P, Chounlamountri N, Perrot V, Belin M-F, Goshima Y, Honnorat J, Thomasset N, Kolattukudy P (2006) Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/- mice. Genes Cells 11:1337&#x2013;1352. 10.1111/j.1365-2443.2006.01024.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2443.2006.01024.x</ArticleId><ArticleId IdType="pubmed">17121542</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZH, Ip NY (2012) Cdk5: a multifaceted kinase in neurodegenerative diseases. Trends Cell Biol 22:169&#x2013;175. 10.1016/j.tcb.2011.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2011.11.003</ArticleId><ArticleId IdType="pubmed">22189166</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17:94&#x2013;102. 10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Hwang AW, Restrepo CR, Yuan C-X, Trojanowski JQ, Lee VMY (2015) An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun 6:5845. 10.1038/ncomms6845</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, Hern&#xe1;ndez F, Eickholt BJ, Nikolic M, Sutherland C (2006) Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 281:16591&#x2013;16598. 10.1074/jbc.M513344200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M513344200</ArticleId><ArticleId IdType="pmc">PMC1805471</ArticleId><ArticleId IdType="pubmed">16611631</ArticleId></ArticleIdList></Reference><Reference><Citation>De Winter F, Vo T, Stam FJ, Wisman LAB, B&#xe4;r PR, Niclou SP, van Muiswinkel FL, Verhaagen J (2006) The expression of the chemorepellent semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol Cell Neurosci 32:102&#x2013;117. 10.1016/j.mcn.2006.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2006.03.002</ArticleId><ArticleId IdType="pubmed">16677822</ArticleId></ArticleIdList></Reference><Reference><Citation>Duplan L, Bernard N, Casseron W, Dudley K, Thouvenot E, Honnorat J, Rogemond V, De Bovis B, Aebischer P, Marin P, Raoul C, Henderson CE, Pettmann B (2010) Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death. J Neurosci 30:785&#x2013;796. 10.1523/JNEUROSCI.5411-09.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5411-09.2010</ArticleId><ArticleId IdType="pmc">PMC6633025</ArticleId><ArticleId IdType="pubmed">20071543</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, Clark HB, Orr HT (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38:375&#x2013;387. 10.1016/s0896-6273(03)00258-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(03)00258-7</ArticleId><ArticleId IdType="pubmed">12741986</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gordon D, Thompson AG, Finelli MJ, Dafinca R, Candalija A, Charles PD, M&#xe4;ger I, Wood MJ, Fischer R, Kessler BM, Gray E, Turner MR, Talbot K (2020) An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiol Dis 144:105050. 10.1016/j.nbd.2020.105050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105050</ArticleId><ArticleId IdType="pubmed">32800996</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM (1995) Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376:509&#x2013;514. 10.1038/376509a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/376509a0</ArticleId><ArticleId IdType="pubmed">7637782</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264:1772&#x2013;1775. 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner-Boblenz A, Schifferer M, Ruepp M-D, Simons M, Niessing D, Madl T, Dormann D (2018) Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell 173:706&#x2013;719.e13. 10.1016/j.cell.2018.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.004</ArticleId><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikezu S, Ingraham Dixie KL, Koro L, Watanabe T, Kaibuchi K, Ikezu T (2020) Tau-tubulin kinase 1 and amyloid-&#x3b2; peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models. Acta Neuropathol Commun 8:12. 10.1186/s40478-020-0890-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-0890-4</ArticleId><ArticleId IdType="pmc">PMC7001309</ArticleId><ArticleId IdType="pubmed">32019603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai S, Takagi Y, Kaneko S, Kurosawa T (2011) Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp Anim 60:481&#x2013;487. 10.1538/expanim.60.481</Citation><ArticleIdList><ArticleId IdType="doi">10.1538/expanim.60.481</ArticleId><ArticleId IdType="pubmed">22041285</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima T, Jitsuki-Takahashi A, Takizawa K, Jitsuki S, Takahashi T, Ohshima T, Goshima Y, Nakamura F (2021) Phosphorylation of collapsin response mediator protein 1 (CRMP1) at tyrosine 504 residue regulates semaphorin 3A-induced cortical dendritic growth. J Neurochem 157:1207&#x2013;1221. 10.1111/jnc.15304</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15304</ArticleId><ArticleId IdType="pubmed">33449368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Taylor JP (2017) Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron 96:285&#x2013;297. 10.1016/j.neuron.2017.07.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.029</ArticleId><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinman E, Holzbaur ELF (2015) Stress-induced CDK5 activation disrupts axonal transport via Lis1/Ndel1/Dynein. Cell Rep 12:462&#x2013;473. 10.1016/j.celrep.2015.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.06.032</ArticleId><ArticleId IdType="pmc">PMC4532378</ArticleId><ArticleId IdType="pubmed">26166569</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, B&#xf6;selt S, Wichmann K, Thau-Habermann N, Zapf A, Knippenberg S, Dengler R, Petri S (2016) The axon guidance protein semaphorin 3A is increased in the motor cortex of patients with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 75:326&#x2013;333. 10.1093/jnen/nlw003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlw003</ArticleId><ArticleId IdType="pubmed">26921371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurnellas MP, Li H, Jain MR, Giraud SN, Nicot AB, Ratnayake A, Heary RF, Elkabes S (2010) Reduced expression of plasma membrane calcium ATPase 2 and collapsin response mediator protein 1 promotes death of spinal cord neurons. Cell Death Differ 17:1501&#x2013;1510. 10.1038/cdd.2010.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2010.54</ArticleId><ArticleId IdType="pmc">PMC3266660</ArticleId><ArticleId IdType="pubmed">20489728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobsiger CS, Garcia ML, Ward CM, Cleveland DW (2005) Altered axonal architecture by removal of the heavily phosphorylated neurofilament tail domains strongly slows superoxide dismutase 1 mutant-mediated ALS. Proc Natl Acad Sci U&#x2009;S&#x2009;A 102:10351&#x2013;10356. 10.1073/pnas.0503862102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0503862102</ArticleId><ArticleId IdType="pmc">PMC1177385</ArticleId><ArticleId IdType="pubmed">16002469</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Zeng K, Zhang C, Fang M, Zhang X, Zhu Q, Wang L, Wang W, Wang X, Chen G (2012) Down-regulation of CRMP-1 in patients with epilepsy and a rat model. Neurochem Res 37:1381&#x2013;1391. 10.1007/s11064-012-0712-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-012-0712-6</ArticleId><ArticleId IdType="pubmed">22359051</ArticleId></ArticleIdList></Reference><Reference><Citation>Maimon R, Ankol L, Gradus Pery T, Altman T, Ionescu A, Weissova R, Ostrovsky M, Tank E, Alexandra G, Shelestovich N, Opatowsky Y, Dori A, Barmada S, Balastik M, Perlson E (2021) A CRMP4-dependent retrograde axon-to-soma death signal in amyotrophic lateral sclerosis. EMBO J 40:e107586. 10.15252/embj.2020107586</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020107586</ArticleId><ArticleId IdType="pmc">PMC8408612</ArticleId><ArticleId IdType="pubmed">34190355</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Tomita M, Ishihama Y (2008) Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res 7:731&#x2013;740. 10.1021/pr700658q</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr700658q</ArticleId><ArticleId IdType="pubmed">18183947</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura F, Kumeta K, Hida T, Isono T, Nakayama Y, Kuramata-Matsuoka E, Yamashita N, Uchida Y, Ogura K-I, Gengyo-Ando K, Mitani S, Ogino T, Goshima Y (2014) Amino- and carboxyl-terminal domains of Filamin-A interact with CRMP1 to mediate Sema3A signalling. Nat Commun 5:5325. 10.1038/ncomms6325</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6325</ArticleId><ArticleId IdType="pubmed">25358863</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura H, Takahashi-Jitsuki A, Makihara H, Asano T, Kimura Y, Nakabayashi J, Yamashita N, Kawamoto Y, Nakamura F, Ohshima T, Hirano H, Tanaka F, Goshima Y (2018) Proteome and behavioral alterations in phosphorylation-deficient mutant collapsin response mediator protein2 knock-in mice. Neurochem Int 119:207&#x2013;217. 10.1016/j.neuint.2018.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2018.04.009</ArticleId><ArticleId IdType="pubmed">29758318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MD, Larivi&#xe8;re RC, Julien JP (2001) Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron 30:135&#x2013;147. 10.1016/S0896-6273(01)00268-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00268-9</ArticleId><ArticleId IdType="pubmed">11343650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomoto M, Konopaske GT, Yamashita N, Aoki R, Jitsuki-Takahashi A, Nakamura H, Makihara H, Saito M, Saigusa Y, Nakamura F, Watanabe K, Baba T, Benes FM, Tobe BTD, Pernia CD, Coyle JT, Sidman RL, Hirayasu Y, Snyder EY, Goshima Y (2021) Clinical evidence that a dysregulated master neural network modulator may aid in diagnosing schizophrenia. Proc Natl Acad Sci U&#x2009;S&#x2009;A 118:e2100032118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346854</ArticleId><ArticleId IdType="pubmed">34330827</ArticleId></ArticleIdList></Reference><Reference><Citation>Numata-Uematsu Y, Wakatsuki S, Nagano S, Shibata M, Sakai K, Ichinohe N, Mikoshiba K, Ohshima T, Yamashita N, Goshima Y, Araki T (2019) Inhibition of collapsin response mediator protein-2 phosphorylation ameliorates motor phenotype of ALS model mice expressing SOD1G93A. Neurosci Res 139:63&#x2013;68. 10.1016/j.neures.2018.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2018.08.016</ArticleId><ArticleId IdType="pubmed">30194029</ArticleId></ArticleIdList></Reference><Reference><Citation>Petratos S, Li Q-X, George AJ, Hou X, Kerr ML, Unabia SE, Hatzinisiriou I, Maksel D, Aguilar M-I, Small DH (2008) The beta-amyloid protein of Alzheimer&#x2019;s disease increases neuronal CRMP-2 phosphorylation by a Rho-GTP mechanism. Brain 131:90&#x2013;108. 10.1093/brain/awm260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm260</ArticleId><ArticleId IdType="pubmed">18000012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O&#x2019;Regan JP, Deng HX (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59&#x2013;62. 10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65 [Suppl 1]:S3&#x2013;S9. 10.1002/ana.21543</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroedicke M, et al.. (2015) Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Res 25:701&#x2013;713. 10.1101/gr.182444.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.182444.114</ArticleId><ArticleId IdType="pmc">PMC4417118</ArticleId><ArticleId IdType="pubmed">25908449</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL (2017) Could sirtuin activities modify ALS onset and progression? Cell Mol Neurobiol 37:1147&#x2013;1160. 10.1007/s10571-016-0452-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-016-0452-2</ArticleId><ArticleId IdType="pubmed">27942908</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539:197&#x2013;206. 10.1038/nature20413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K, Kolattukudy P, Honnorat J, Goshima Y (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer&#x2019;s disease. Genes Cells 10:165&#x2013;179. 10.1111/j.1365-2443.2005.00827.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2443.2005.00827.x</ArticleId><ArticleId IdType="pubmed">15676027</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, et al.. (2012) EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 18:1418&#x2013;1422. 10.1038/nm.2901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2901</ArticleId><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S, Ageta-Ishihara N, Nagatsu S, Takao K, Komine O, Endo F, Miyakawa T, Misawa H, Takahashi R, Kinoshita M, Yamanaka K (2014) SIRT1 overexpression ameliorates a mouse model of SOD1-linked amyotrophic lateral sclerosis via HSF1/HSP70i chaperone system. Mol Brain 7:62. 10.1186/s13041-014-0062-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-014-0062-1</ArticleId><ArticleId IdType="pmc">PMC4237944</ArticleId><ArticleId IdType="pubmed">25167838</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita N, Morita A, Uchida Y, Nakamura F, Usui H, Ohshima T, Taniguchi M, Honnorat J, Thomasset N, Takei K, Takahashi T, Kolattukudy P, Goshima Y (2007) Regulation of spine development by semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response mediator protein 1. J Neurosci 27:12546&#x2013;12554. 10.1523/JNEUROSCI.3463-07.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3463-07.2007</ArticleId><ArticleId IdType="pmc">PMC6673320</ArticleId><ArticleId IdType="pubmed">18003833</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita N, Takahashi A, Takao K, Yamamoto T, Kolattukudy P, Miyakawa T, Goshima Y (2013) Mice lacking collapsin response mediator protein 1 manifest hyperactivity, impaired learning and memory, and impaired prepulse inhibition. Front Behav Neurosci 7:216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873514</ArticleId><ArticleId IdType="pubmed">24409129</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>